Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights
Journal of Neuropathology & Experimental Neurology · 01.09.2024 · 83 (9) · 708-721
DOI: 10.1093/jnen/nlae050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, online erschienen am 25.06.2024. Verfasst von Bette K Kleinschmidt-DeMasters. Beteiligte Einrichtung: Departments of Pathology, Neurology, Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Adenoma, Immunohistochemistry, Ganglioneuroma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Mixed pituitary adenoma/PitNET-gangliocytomas (PA/PitNET-GC) have been reported in small series over the past 20 years; some had limited immunohistochemistry (IHC) data. We interrogated our experience over 20 years, focusing on patterns of the GC component and IHC results for anterior pituitary hormones, transcription factors, NFP, and CAM5.2. A search of cases from 2002 to 2023 yielded 20 cases: 7M:13F, ages 20–71 years; 17 macroadenomas, 1 microadenoma, 2 ectopic. GC was co-associated with 4 corticotroph, 2 densely granulated lactotroph, 5 mixed lactotroph-somatotroph, 1 immature PIT1-lineage tumor, and 8 sparsely granulated GH; the latter all had a minor lactotroph component. Patterns were: discrete nodular foci of GC (9/20), extensive GC differentiation often overshadowing the PA/PitNET (7/20), and intimate admixture of smaller bands of neuropil and individual metaplastic ganglion cells within PA/PitNET (4/20). NFP highlighted small cohesive regions of neuropil and identified greater axonal content, including individual axons within “pure” PA/PitNET areas, than appreciated on H&E. CAM5.2 IHC often revealed cells with neuronal morphologies to a greater extent than NFP and in different areas within the same tumor. These data suggest that the combined use of NFP and CAM5.2 IHC best reveals transition from PA to GC phenotype, with CAM5.2 positivity reflecting earlier stages of transformation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Pathology, Neurology, Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Zitieren
APA
Kleinschmidt-DeMasters, B. K. (2024). Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights. Journal of Neuropathology & Experimental Neurology, 83(9), 708-721. https://doi.org/10.1093/jnen/nlae050
Vancouver
Kleinschmidt-DeMasters BK. Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights. Journal of Neuropathology & Experimental Neurology. 2024;83(9):708-721. doi:10.1093/jnen/nlae050
BibTeX
@article{KleinschmidtDeMasters2024,
author = {Kleinschmidt-DeMasters, Bette K},
title = {Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2024},
volume = {83},
number = {9},
pages = {708--721},
doi = {10.1093/jnen/nlae050}
}
EUVIMED